Hereditary hemorrhagic telangiectasia

Feb. 07, 2025

HHT care at Mayo Clinic

Mayo Clinic is a hereditary hemorrhagic telangiectasia (HHT) Center of Excellence. This means that CureHHT has designated Mayo Clinic as a center that provides state-of-the-art care and has experts in diagnosing and treating all aspects of this disorder in children and adults. Mayo Clinic provides whole-person care that meets the needs of people and families with HHT.

Your Mayo Clinic care team

At Mayo Clinic, specialists from many departments work together to diagnose and treat people with hereditary hemorrhagic telangiectasia (HHT). These include specialists in pulmonary medicine; clinical genomics; pediatric pulmonary; cardiovascular disease; neurology; neurosurgery; Otolaryngology (ENT)/Head and Neck Surgery; gastroenterology and hepatology; and radiology.

Advanced diagnosis and treatment

Mayo Clinic offers in-house comprehensive genetic testing for HHT and similar vascular malformation syndromes. This test (LAB 11256) tests for common and rare genetic mutations associated with HHT and similar vascular disorders. Mayo Clinic's Center for Individualized Medicine offers personalized consultations for rare or undiagnosed conditions. Mayo pharmacists compound a special rose geranium in sesame oil nose spray for nosebleeds of people with HHT.

Expertise and rankings

HHT is a rare disease that can be difficult to diagnose. People with this uncommon disorder sometimes don't receive a correct diagnosis for more than a decade.

Mayo Clinic is a hereditary hemorrhagic telangiectasia (HHT) Center of Excellence. It's the only HHT Center of Excellence in Minnesota and one of the few in the Upper Midwest. This means that Mayo Clinic has been designated by Cure HHT as having expertise in diagnosing and treating all aspects of this disorder in both children and adults.

Mayo Clinic specialists see hundreds of people with HHT and provides state-of-the-art care for HHT.

  1. Kitchens CS, et al., eds. Hereditary hemorrhagic telangiectasia. In: Consultative Hemostasis and Thrombosis. 4th ed. Philadelphia, Pa.: Elsevier; 2019. https://www.clinicalkey.com. Accessed Aug. 1, 2024.
  2. Shovlin CL. Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome). https://www.uptodate.com/contents/search. Accessed Aug 1, 2024.
  3. Ferri FF. Hereditary hemorrhagic telangiectasia. In: Ferri's Clinical Advisor 2025. Elsevier; 2025. https://www.clinicalkey.com. Accessed Aug 1, 2024.
  4. AskMayoExpert. Hereditary hemorrhagic telangiectasia. Mayo Clinic; 2023.
  5. Faughnan ME, et al. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Annals of Internal Medicine. 2020; doi:10.7326/M20-1443.
  6. North American HHT Centers of Excellence. CureHHT. https://directory.curehht.org/hht-centers. Accessed Aug. 1, 2024.
  7. McDonald J, et al. Hereditary hemorrhagic telangiectasia. Gene Review. 2021. https://www.ncbi.nlm.nih.gov/books/NBK1351/. Accessed August 1, 1014.
  8. Nimmagadda R. Allscripts EPSi. Mayo Clinic. Sept. 17, 2024.
  9. Medical review (expert opinion). Mayo Clinic. Oct. 1, 2024.